<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl14" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Stromal cells</th><th>BRAF/MEK inhibitor</th><th>MET inhibitor</th><th>Mean</th><th>SEM</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td>None</td><td>Vehicle</td><td>Vehicle</td><td>100</td><td>0.00</td><td>0.00</td><td>3</td></tr><tr><td>None</td><td>Vehicle</td><td>Crizotinib</td><td>97.4</td><td>0.39</td><td>0.70</td><td>3</td></tr><tr><td>None</td><td>Vehicle</td><td>PHA-665752</td><td>97.4<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>0.39<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>0.70<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>None</td><td>PLX4720</td><td>Vehicle</td><td>32.2</td><td>10.8</td><td>18.7</td><td>3</td></tr><tr><td>None</td><td>PLX4720</td><td>Crizotinib</td><td>28.4</td><td>8.81</td><td>15.3</td><td>3</td></tr><tr><td>None</td><td>PLX4720</td><td>PHA-665752</td><td>28.4<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>8.81<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>15.3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>None</td><td>PD184352</td><td>Vehicle</td><td>24.4</td><td>13.2</td><td>22.9</td><td>3</td></tr><tr><td>None</td><td>PD184352</td><td>Crizotinib</td><td>26.6</td><td>2.73</td><td>4.70</td><td>3</td></tr><tr><td>None</td><td>PD184352</td><td>PHA-665752</td><td>26.6<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>2.73<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>4.70<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>LL 86</td><td>Vehicle</td><td>Vehicle</td><td>99.2</td><td>2.05</td><td>3.60</td><td>3</td></tr><tr><td>LL 86</td><td>Vehicle</td><td>Crizotinib</td><td>99.1</td><td>3.63</td><td>6.30</td><td>3</td></tr><tr><td>LL 86</td><td>Vehicle</td><td>PHA-665752</td><td>99.1<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3.63<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>6.30<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>LL 86</td><td>PLX4720</td><td>Vehicle</td><td>91.0</td><td>9.32</td><td>16.1</td><td>3</td></tr><tr><td>LL 86</td><td>PLX4720</td><td>Crizotinib</td><td>33.4</td><td>7.28</td><td>12.6</td><td>3</td></tr><tr><td>LL 86</td><td>PLX4720</td><td>PHA-665752</td><td>33.4<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>7.28<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>12.6<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>LL 86</td><td>PD184352</td><td>Vehicle</td><td>56.9</td><td>11.1</td><td>19.2</td><td>3</td></tr><tr><td>LL 86</td><td>PD184352</td><td>Crizotinib</td><td>25.4</td><td>3.64</td><td>6.30</td><td>3</td></tr><tr><td>LL 86</td><td>PD184352</td><td>PHA-665752</td><td>25.4<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3.64<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>6.30<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>CCD-1090Sk</td><td>Vehicle</td><td>Vehicle</td><td>99.7</td><td>0.80</td><td>1.40</td><td>3</td></tr><tr><td>CCD-1090Sk</td><td>Vehicle</td><td>Crizotinib</td><td>100.8</td><td>3.40</td><td>5.90</td><td>3</td></tr><tr><td>CCD-1090Sk</td><td>Vehicle</td><td>PHA-665752</td><td>100.8<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3.40<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>5.90<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>CCD-1090Sk</td><td>PLX4720</td><td>Vehicle</td><td>31.1</td><td>8.40</td><td>14.5</td><td>3</td></tr><tr><td>CCD-1090Sk</td><td>PLX4720</td><td>Crizotinib</td><td>27.1</td><td>6.10</td><td>10.6</td><td>3</td></tr><tr><td>CCD-1090Sk</td><td>PLX4720</td><td>PHA-665752</td><td>27.1<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>6.10<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>10.6<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr><tr><td>CCD-1090Sk</td><td>PD184352</td><td>Vehicle</td><td>23.7</td><td>10.2</td><td>17.7</td><td>3</td></tr><tr><td>CCD-1090Sk</td><td>PD184352</td><td>Crizotinib</td><td>26.9</td><td>10.1</td><td>17.5</td><td>3</td></tr><tr><td>CCD-1090Sk</td><td>PD184352</td><td>PHA-665752</td><td>26.9<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>10.1<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>17.5<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td><td>3<xref ref-type="table-fn" rid="tblfn6"><sup>a</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><label>a</label><p>All PHA-665752 treatment values were made the same as the corresponding crizotinib treatment as these inhibitors are assumed to have the same effect. PHA-665752 is an additional MET inhibitor added to the experimental design.</p></fn></table-wrap-foot></table-wrap>